193 related articles for article (PubMed ID: 18172759)
1. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.
Ihnen M; Müller V; Wirtz RM; Schröder C; Krenkel S; Witzel I; Lisboa BW; Jänicke F; Milde-Langosch K
Breast Cancer Res Treat; 2008 Dec; 112(3):419-27. PubMed ID: 18172759
[TBL] [Abstract][Full Text] [Related]
2. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
[TBL] [Abstract][Full Text] [Related]
3. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
[TBL] [Abstract][Full Text] [Related]
4. Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis.
Witzel I; Schröder C; Müller V; Zander H; Tachezy M; Ihnen M; Jänicke F; Milde-Langosch K
Oncology; 2012; 82(6):305-12. PubMed ID: 22555284
[TBL] [Abstract][Full Text] [Related]
5. Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion.
Jezierska A; Olszewski WP; Pietruszkiewicz J; Olszewski W; Matysiak W; Motyl T
Med Sci Monit; 2006 Jul; 12(7):BR245-56. PubMed ID: 16810131
[TBL] [Abstract][Full Text] [Related]
6. ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive nature of breast cancer cells, a potential connection to bone metastasis.
Davies S; Jiang WG
Anticancer Res; 2010 Apr; 30(4):1163-8. PubMed ID: 20530423
[TBL] [Abstract][Full Text] [Related]
7. Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients.
Tachezy M; Zander H; Gebauer F; Marx A; Kaifi JT; Izbicki JR; Bockhorn M
J Surg Res; 2012 Sep; 177(1):e15-20. PubMed ID: 22482754
[TBL] [Abstract][Full Text] [Related]
8. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
[TBL] [Abstract][Full Text] [Related]
9. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
11. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy.
Jezierska A; Matysiak W; Motyl T
Med Sci Monit; 2006 Aug; 12(8):BR263-73. PubMed ID: 16865058
[TBL] [Abstract][Full Text] [Related]
12. Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients.
Burandt E; Bari Noubar T; Lebeau A; Minner S; Burdelski C; Jänicke F; Müller V; Terracciano L; Simon R; Sauter G; Wilczak W; Lebok P
Oncol Rep; 2014 Dec; 32(6):2628-34. PubMed ID: 25270339
[TBL] [Abstract][Full Text] [Related]
13. [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy].
Kilic E; Milde-Langosch K; Müller V; Wirtz R; Ihnen M
Pathologe; 2008 Nov; 29 Suppl 2():347-52. PubMed ID: 18810438
[TBL] [Abstract][Full Text] [Related]
14. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
Rody A; Karn T; Ruckhäberle E; Müller V; Gehrmann M; Solbach C; Ahr A; Gätje R; Holtrich U; Kaufmann M
Breast Cancer Res Treat; 2009 Feb; 113(3):457-66. PubMed ID: 18340528
[TBL] [Abstract][Full Text] [Related]
15. Expression of the cell to cell adhesion molecule, ALCAM, in breast cancer patients and the potential link with skeletal metastasis.
Davies SR; Dent C; Watkins G; King JA; Mokbel K; Jiang WG
Oncol Rep; 2008 Feb; 19(2):555-61. PubMed ID: 18202807
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data.
Ruckhäberle E; Karn T; Engels K; Turley H; Hanker L; Müller V; Schmidt M; Ahr A; Gaetje R; Holtrich U; Kaufmann M; Rody A
Eur J Cancer; 2010 Feb; 46(3):549-57. PubMed ID: 20022486
[TBL] [Abstract][Full Text] [Related]
17. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma.
Wachowiak R; Mayer S; Kaifi J; Gebauer F; Izbicki JR; Lacher M; Bockhorn M; Tachezy M
Anticancer Res; 2016 Aug; 36(8):3991-5. PubMed ID: 27466504
[TBL] [Abstract][Full Text] [Related]
19. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
Kristiansen G; Pilarsky C; Wissmann C; Kaiser S; Bruemmendorf T; Roepcke S; Dahl E; Hinzmann B; Specht T; Pervan J; Stephan C; Loening S; Dietel M; Rosenthal A
J Pathol; 2005 Feb; 205(3):359-76. PubMed ID: 15532095
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer.
Burkhardt M; Mayordomo E; Winzer KJ; Fritzsche F; Gansukh T; Pahl S; Weichert W; Denkert C; Guski H; Dietel M; Kristiansen G
J Clin Pathol; 2006 Apr; 59(4):403-9. PubMed ID: 16484444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
